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Actinic keratoses (AK) occur frequently; however, real-
life clinical data on personalized treatment choice and 
costs are scarce. This multicentre one-year observatio-
nal study investigated patient-characteristics, cost and 
effectiveness of methylaminolaevulinate photodynamic 
therapy (MAL-PDT), imiquimod (IMI) and 5-fluoro ur-
acil (5-FU) in patients with AKs on the face/scalp. A total 
of 104 patients preferred MAL-PDT, 106 preferred IMI 
and 110 preferred 5-FU. At baseline, significant differen-
ces between treatment groups were found; most patients 
were severely affected (mean 32.5 AK in PDT-group, 20.2 
in IMI-group, 22.8 in 5-FU-group). A mean reduction in 
lesions of 81% after MAL-PDT, 82% after IMI and 88% 
after 5-FU was found after one year. Annual costs were 
€1,950 for MAL-PDT, €877 for IMI and €738 for 5-FU. 
These results show that, compared with clinical trials, in 
the real-life clinical setting AK patients are usually more 
severely affected and treatment costs are much higher. 
Furthermore, patient characteristics are important fac-
tors in treatment choice. Key words: actinic keratoses; 
treatment; cost; effectiveness; patient characteristics.
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Actinic keratoses (AKs) are chronically recurrent pre-
malignant lesions that occur mainly on chronically sun-
exposed skin in Caucasians. In a recent study conducted 
in the Netherlands, a prevalence of AKs of 49% in men 
and 28% in women was found in a cohort of the general 
population aged 45 years or above (1). Studies performed 
in other countries also show that AK frequently occurs 
in the elderly population (2, 3). Because of the potential 
of AK to develop into squamous cell carcinoma (SCC), 
treatment is recommended. Given the high incidence of 
AKs and their predominant occurrence in the head and 
neck region, a cost-effective therapy with good cosmetic 
results is needed. 
Treatment can be directed at individual lesions, and 
cryotherapy is the most common treatment used. For 
patients with multiple AKs and in field cancerization, a 
field-directed approach is considered more appropriate, 
e.g. photodynamic therapy (PDT), imiquimod cream 
(IMI) or 5-fluorouracil cream (5-FU) (4). Within the 
group of field-directed treatments no specific patient cha-
racteristics to guide treatment choice have been defined. 
Although personalized medicine and costs are 
nowadays of great importance in treatment choice, only 
a few studies on the cost of field-directed treatments 
have been published (5–7). Most of these studies are 
based on the results of randomized controlled trials 
(RCTs), in which selected patients with few AKs are 
treated and treatment choice is based on randomization. 
It is also known that patients in RCTs do not provide 
an adequate reflection of real-life clinical practice (8). 
The present study aimed to investigate whether patient 
characteristics play a directive in treatment choice in 
methylaminolaevulinate (MAL)-PDT, IMI and 5-FU in 
real-life practice in patients with AKs on the face and/or 
scalp. Furthermore, data on the cost and effectiveness 
of these treatment modalities were collected. 
MATERIALS AND METHODS
Study design
Multicentre, 1-year observational study, conducted in 2 general 
and 2 university hospitals in the Netherlands. 
Patients
Patients of 18 years and older, with a clinical diagnosis of AKs 
on the face and/or scalp region, suitable for field-directed treat-
ment (AK in close proximity from each other), were included in 
the period October 2009 to June 2011. Patients were excluded 
in case of pregnancy, breast-feeding or contra-indications to 
field therapy. The study was approved by the local ethics com-
mittee of all participating institutions. All patients gave written 
consent to participate in the study. 
Treatment modalities
Treatment choice between MAL-PDT, IMI and 5-FU was based 
on patients’ preference (after explanation on the treatment op-
tions) in combination with the clinical appearance of AKs. The 
use of treatment was standardized in the participating hospitals. 
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PDT. During one week prior to PDT, patients were pre-treated 
with a keratolytic ointment (10% salicylic acid in petrolatum) to 
remove hyperkeratosis. On the PDT day (at the day-care centre), 
remaining hyperkeratoses were carefully removed by curettage 
and the skin was wiped with alcohol. In addition, a thin layer (ap-
proximately 1 mm) MAL cream (Metvix®; Galderma) was applied 
on the treatment area, and covered with an occlusive dressing and 
tinfoil to prevent influence of light. After 3 h the dressing and 
cream were removed and the skin was illuminated with a red light 
(632 nm, 37 J/cm2) from a light-emitting diode light source (Akti-
lite®). Three months after PDT, clearance of AKs was assessed. In 
case of remaining AKs, additional treatment could be performed. 
Imiquimod. IMI (Aldara®, MEDA) was used at home 3 times 
per week (Monday, Wednesday and Friday) for 4 consecutive 
weeks. Cream was applied prior to normal sleeping hours, and 
removed in the morning, after approximately 8 h. Sufficient 
cream was applied to cover the treatment area (never more 
than 1 sachet). In case of an intense local reaction, treatment 
was interrupted and continued after recovery. Four weeks after 
finishing treatment, clearance of AKs was assessed. In case 
of remaining AKs, additional treatment could be performed.
5-FU cream. A sufficient amount of 5-FU cream was applied at 
home, twice daily, to cover the treatment area, until erosions, red-
ness and crusting occurred (duration 2–4 weeks). After 3 months, 
in case of remaining AKs, additional treatment could be performed.
Subsequent and concomitant treatment. In case of AKs re-
maining after finishing the initial treatment of choice, patients 
received subsequent treatment, which could be a treatment 
other than the initial treatment. Depending on the number of 
AKs and the patient’s preference, this could be lesion-directed 
(cryotherapy) or field-directed therapy. In case side-effects oc-
curred (e.g. itching, infections) patients received concomitant 
treatment, e.g. topical corticosteroids or antibiotics. 
Design
All patients were included and followed by the same 2 investi-
gators. Patients were included at baseline (M0), prior to the 
start of the treatment. Follow-up evaluation was scheduled at 
3 months (M3) and 12 months (M12) after treatment start. If 
necessary, extra appointments were made at the outpatient clinic 
(e.g. in case of subsequent treatment). Patients treated with IMI 
were also seen at 8 weeks after treatment start to evaluate the 
effect of the treatment. Effectiveness of the treatment for study 
purpose was evaluated only at M3 and M12. 
At baseline, the following data were collected: age, sex, race 
and Fitzpatrick skin type of the patient; location, number and 
severity of AKs (according to the Olsen classification), num-
ber of diagnostic biopsies, previous AK treatments, patients’ 
medical history and medication use. Presence of hypopigmen-
tation, hyperpigmentation, atrophy, erythema, induration, scar 
formation, hyperkeratosis, and desquamation of the treatment 
area were scored.
Outcomes
Subjects were evaluated at M3 and M12. The following infor-
mation was recorded:
Effectiveness of treatment 
• Lesion response: the total number of AKs was evaluated by in-
spection, palpation and photography of the treatment area. Lesion 
response was registered as complete in case of 100% clearance.
• Cosmetic results: cosmetic score was classified as excellent 
when there was no scarring, atrophy, or induration and no 
or slight occurrence of erythema or change in pigmentation. 
Consumption of care and associated costs. All costs related to 
the treatment of AK in the face/scalp during one year were col-
lected. Total costs were calculated by multiplying every item 
with the unit costs. Standard unit costs as established by the 
National Healthcare Insurance Board of the Netherlands were 
used where possible, otherwise costs were gathered from the 
hospital administration, and converted to the 2011 price level (9). 
Where relevant, different costs were used for general hospitals 
and university hospitals (general hospital €66 for a consultation, 
university hospital €134) (10). MAL-PDT costs were based on 
the costs for day-care admission (€251) (10), costs for grams of 
MAL used (tube 2 g €272, weighed before and after treatment), 
standard materials used (e.g. occlusive dressing, light source), 
and the costs for personnel. IMI was prescribed per treatment 
cycle, including 12 sachets (€60). For 5-FU one tube for the 
whole treatment area could be used (€41). The cost of a diagnostic 
biopsy was €150, including costs for pathological evaluation. 
Mean costs per patient were calculated over a one-year period 
for each treatment group. In addition, mean costs per individual 
AK lesion were calculated. 
Analysis
Study size determination. A sample size calculation was performed 
in order to obtain a sufficiently precise estimate of the proportion 
of patients in remission at 1-year follow-up. This was based on the 
following assumptions: an overall remission percentage of 70% 
(86% for IMI, 57% for 5-FU and 88–89% for PDT) (11, 12) and 
a 2-sided 95% confidence interval with a maximum of 60–80%. 
This resulted in a sample size of 81 patients (α = 0.05) per treat-
ment group. To control for possible loss to follow-up (LTFU), a 
minimum of 100 patients per treatment group was included.
Statistical methods. Data were collected in a web application 
(Trial Registry Information and Administration System). For 
further analysis, data were entered into Statistical Package for 
Social Science (SPSS 20.0, IBM Corp, Armonk, NY, USA). 
Descriptive statistics and crosstabs (χ2, Fisher’s exact test) 
were performed to analyse the differences between the study 
groups at baseline. p-values < 0.05 were considered statistically 
significant in the comparison between baseline characteristics. 
Based on the observational design of the study, and the fact that 
our goal was to describe real-life data rather than comparing 
effectiveness between groups, follow-up results were only 
described per treatment group. All patients were analysed ac-
cording to the intention-to-treat (ITT) principle.
RESULTS
Study population
As this study had an observational design, most patients 
with field AK were willing to participate, thus the out-
patient clinic population was well represented. Treat-
ment choice was based on the patient’s preference and 
the clinical appearance of the AK; no randomization 
was performed. A total of 320 patients was included 
in the study: 104 patients were initially treated with 
MAL-PDT, 106 with IMI and 110 with 5-FU (Fig. S11). 
In one of the general hospitals no PDT was performed. 
Five patients withdrew from the study directly after 
inclusion. Ninety-three patients who were treated with 
MAL-PDT, 101 patients who were treated with IMI, 
and 98 who were treated with 5-FU attended the M3 
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2216
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visit (Fig. S11). At M12, 17 more 
patients were LTFU (PDT 3, IMI 
5 and 5-FU 9 patients). 
As may be expected in case 
of a naturalistic study, statis-
tically significant differences 
were found between the baseline 
characteristics of the treatment 
groups (Table I). Patients treated 
with MAL-PDT had significantly 
more AKs, a larger affected area 
(face in addition to scalp), and 
more previous AK treatments. 
Those treated with IMI were 
the youngest and had the lowest 
number of AKs. Patients treated 
with 5-FU had the worst baseline 
cosmetic scores. 
Lesion response
The mean percentage of lesion 
reduction, absolute number of le-
sion reduction, and total number 
of full responders after 3 months 
(M3) and 12 months (M12) are 
shown in Table II. Patients treated with MAL-PDT sho-
wed the highest absolute number of lesion reduction. 
Patients treated with 5-FU demonstrated the highest 
percentage of lesion reduction and the highest number 
of full responders at both M3 and M12. 
Cosmetic results
At M12, 65.6% of patients treated with MAL-PDT, 
64.9% of patients treated with IMI, and 54.9% of patients 
treated with 5-FU had an excellent cosmetic outcome. 
Consumption of care and costs
An overview of subsequent treatments is shown in 
Table III. Patients initially treated with MAL-PDT had 
the highest number of subsequent treatments. In only 
a few patients was a second cycle with PDT or IMI, as 
prescribed in the treatment protocol, performed. Since 
most often only a few isolated AK lesions remained, 
patients were almost always subsequently treated 
with cryotherapy. Two patients (MAL-PDT and IMI 
group) were subsequently treated with CO2 laser (not 
mentioned in the table). 
An overview of treatment costs per patient is shown 
in Table IV. The mean cost per individual AK lesion 
was €87 (range €9.9–698.3) for MAL-PDT, €71 (range 
€16.0–527.5) for IMI, and €55 (range €11.2–380.0) for 
treatment with 5-FU.
DISCUSSION 
The present study demonstrates which treatment patients 
with multiple AKs currently receive in real-life clinical 
Table I. Baseline characteristics of patients treated with methylaminolaevulinate photo-
dynamic therapy (MAL-PDT), imiquimod cream (IMI) and 5-fluorouracil cream (5-FU)
MAL-PDT (n = 104) IMI (n = 106) 5-FU (n = 110) p-value 
Sex (male), n (%) 74 (71.2) 72 (67.9) 92 (83.6) 0.020
Age, mean ± SD 70.4 ± 8.1 68.5 ± 9.2 73.2 ± 8.1 0.000
Skin type (Fitzpatrick), n (%)
  Type 1
  Type 2
  Type 3
35 (34)
62 (60.2)
6 (5.8)
27 (25.7)
69 (65.7)
 9 (8.6)
13 (11.8)
87 (79.1)
10 (9.1)
0.004
History, n (%) 
  Bowen’s disease (≥ 1)
  Basal cell carcinoma (≥ 1)
  Squamous cell carcinoma (≥ 1)
23 (22.1)
39 (37.5)
15 (14.4)
7 (6.6)
25 (23.6)
9 (8.5)
18 (16.4)
34 (30.9)
24 (21.8)
0.006
0.091
0.023
AK – Olsen (grade), n (%)
  1
  2
  3
71 (68.3)
31 (29.8)
2 (1.9)
60 (56.6)
40 (37.7)
 6 (5.7)
64 (58.2)
35 (31.8)
11 (10.0)
0.079
AK location, n (%)
 Scalp
 Face
 Face and scalp
22 (21.2)
54 (51.9)
28 (26.9)
36 (34.0)
63 (59.4)
 7 (6.6)
48 (43.6)
56 (50.9)
 6 (5.5)
0.000
AK
 Lesions, n, mean ± SD
 Lesions/size area, mm, mean ± SD
32.48 ± 18.38
0.15 ± 0.06
20.22 ± 16.00
0.14 ± 0.10
22.78 ± 15.67
0.11 ± 0.06
0.000
0.000
Previous treatment, n (%) 62 (59.6) 45 (42.5) 61 (55.5) 0.034
Cosmetic score, mean ± SD 4.47 ± 2.64 4.29 ± 2.24 5.37 ± 2.74 0.005
Co-morbidity, mean ± SD 2.21 ± 1.81 1.76 ± 1.56 1.70 ± 1.44 0.097
SD: standard deviation; AK: actinic keratoses.
Table III. Number of subsequent treatments during 1-year follow-up
MAL-PDT 
n = 91 
n (%)
IMI 
n = 96 
n (%)
5-FU 
n = 92 
n (%)
Cryotherapy* 71 (78.0) 68 (70.8) 55 (59.8)
5-FU* 8 (8.8) 3 (3.1) 12 (13.0)
IMI* 5 (5.5) 13 (13.5) 2 (2.2)
MAL-PDT* 11 (12.1) 2 (2.1) 1 (1.1)
Total* 75 (82.4) 71 (74.0) 61 (66.3)
*Percentage per treatment group.
MAL-PDT: methylaminolaevulinate photodynamic therapy; IMI: imiquimod 
cream; 5-FU: 5-fluorouracil cream.
Table II. Lesion reduction of actinic keratoses in patients treated 
with methylaminolaevulinate photodynamic therapy (MAL-PDT), 
imiquimod cream (IMI) and 5-fluorouracil cream (5-FU)
MAL-PDT IMI 5-FU
Number of lesion reduction at:
  M3, absolute numbers (SD) 23.90 (14.6) 15.70 (13.0) 19.66 (13.8)
  M12, absolute numbers (SD) 25.81 (16.3) 15.14 (11.9) 19.34 (13.6)
Mean percentage of lesion reduction at:
  M3, % (SD) 79.39 (22.3) 80.00 (24.7) 89.53 (18.9)
  M12, % (SD) 81.12 (22.4) 81.65 (23.4) 88.45 (15.8)
Total number of full responders at:
  M3, n (%) 24 (25.8) 34 (34.0) 52 (54.2)
  M12, n (%) 19 (20.7) 35 (36.1) 37 (41.1)
SD: standard deviation; M3: 3 months after treatment; M12: 12 months 
after treatment.
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situations, how these patients fare in terms of lesion load 
and cosmetic outcome, and what costs are incurred. 
Differences were found in patient characteristics 
between the treatment groups. Patients who were 
much more severely affected, with a number of AKs, 
who had had more previous treatments, and a higher 
overall number of previous skin tumours, were more 
often treated with MAL-PDT. We also noted more co-
morbidities in this patient group. The youngest patients, 
who were least severely affected by AKs and previous 
treatments, were more frequently treated with IMI. 
Male patients, those of older age, with more previous 
SCCs, and worse cosmetic scores at M0, were most 
often treated with 5-FU. 
MAL-PDT is registered for AK treatment when other 
treatments are considered less appropriate. Therefore, it is 
not surprising that patients in the PDT group were more 
severely affected and had had more previous treatments. 
Compared with patients treated with IMI, the number of 
AKs was 60% higher in the PDT group, compared with 
patients treated with 5-FU, the number of AKs was 43% 
higher in the PDT group. It is well known that these AK 
fields (field cancerization) are more difficult to treat and 
have a higher potential for recurrence, and that multiple 
initial treatments are recommended in these patients 
(13–15). The higher number of previous treatments in the 
PDT patient group may thus be a consequence of rapid 
recurrences and/or therapy-resistant AK. 
Another difference between PDT and the other treat-
ments is that PDT is an in-hospital treatment. Patients 
who are unwilling or unable to treat themselves with IMI 
or 5-FU will choose PDT. This may explain the larger 
treatment area and the higher number of co-morbidities 
in the MAL-PDT group, since these might be patients 
who prefer more assistance with their treatment.
With respect to consumption of care, it was found 
that patients treated with MAL-PDT had more pre-
treatment consultations. This may be because one of the 
university hospitals planned a standard pre-PDT visit 
for instructions. This is not standard in other hospitals. 
Furthermore, treatment costs for MAL-PDT were the 
highest. This is mainly due to the high costs of MAL 
cream and costs related to day-care admission. In pa-
tients with large treatment areas, multiple appointments 
were necessary to treat all lesions. 
The number of full responders in the present study is 
lower than in previous clinical trials (11, 16). This may 
be because there is a striking difference in the number 
of AKs at baseline (approximately 7 in previous studies, 
compared with approximately 25 in the present study). 
An earlier study from our group, in which patients 
with AK were treated with MAL-PDT, showed that 
patients in whom therapy failed, had significantly higher 
numbers of AK at baseline (13). This may have an im-
portant influence on overall efficacy. Furthermore, the 
follow-up period and treatment regimen were different 
from previous trials. The official treatment protocol for 
5-FU prescribes a single treatment session, whereas for 
MAL-PDT and IMI an additional session after evalua-
tion may be part of the initial treatment session. In our 
study it was found that, in clinical practice, cryotherapy 
is more often used as a subsequent treatment instead of 
an additional cycle of MAL-PDT or IMI. 
Compared with previous studies of field-treatment for 
AK, different costs were found. In a study by Annemans 
et al. (5) cost per AK lesion after 6 months’ follow-up 
and treatment with MAL-PDT was €58. Other studies 
performed were based on a decision analytical approach 
or assumptions on the number of treatments (6, 7). Except 
for Gold’s study, in which a standard second treatment 
cycle was calculated, treatment costs in the literature 
were lower than the costs found in our study. Although 
the published studies were performed in other countries, 
additional factors may explain the differences in costs. 
Only one of these studies is observational, with a follow-
up of only 6 months (5). In addition, a smaller spectrum 
of costs was included (e.g. no subsequent treatment, 
no treatment of recurrences). Moreover, patients in the 
present study were more severely affected.
The aim of our study was to assess the costs and ef-
fectiveness of the various treatment modalities as used 
in clinical practice for patients with multiple AK. The 
appropriate design for such a study is an observational 
longitudinal study, monitoring treatment effects and 
costs as they arise in practice. The disadvantage of 
such a design is that many patients received additional 
treatment for their AK, as AK is a chronic and recurrent 
disease, therefore the reduction in lesion number at M12 
was influenced by subsequent treatments. However, 
our aim was not to demonstrate the efficacy of a single 
treatment modality alone.
Another limitation may be the fact that the number of 
AKs assessed at M3 and M12 were all AKs present in 
the treatment area, including new lesions. Other study 
designs mainly assessed the response and recurrences 
of specific lesions. However, to calculate the costs for 
Table IV. Costs (€) per treatment group; methylaminolaevulinate 
photodynamic therapy (MAL-PDT), imiquimod cream (IMI), and 
5-fluorouracil cream (5-FU)
MAL-PDT 
Mean ± SD (range)
IMI 
Mean ± SD (range)
5-FU 
Mean ± SD (range)
Outpatient 
clinic visits
754.31 ± 275.58
(198.99–1,604.40)
627.55 ± 26.36
(265.32–1,203.30)
590.74 ± 27.54
(198.99–1,337.0)
Biopsies 22.80 ± 9.54
(0.0–781.7)
12.26 ± 6.04
(0.0–469.02)
21.67 ± 6.97
(0.0–312.68)
Treatment 984.11 ± 56.60
(0.0–2,704.41)
99.50 ± 4.50
(59.59–238.36)
41.14 ± 0.0
(41.14–41.14)
Concomitant 
treatment
4.73 ± 1.13
(0.0–47.69)
2.34 ± 0.51
(0.0–24.40)
2.55 ± 0.43
(0.0–24.50)
Subsequent 
treatment
180.83 ± 25.30
(0.0–1,432.38)
130.48 ± 22.60
(0.0–1550.25)
79.98 ± 10.03
(0.0–538.58)
Total 1,949.90 ± 75.52
(534.34–4,127.83)
877.17 ± 43.49
(329.98–3,332.72)
738.41 ± 34.29
(306.46–1,875.20)
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field-directed treatment in patients with multiple lesions, 
it is more appropriate to include all lesions appearing in 
the treatment area, since they all need treatment. 
Conclusion
The present observational study shows that, in real-life 
clinical practice, patients with AK are more severely 
affected than patients in clinical trials and that the 
costs of field-directed treatment are much higher. This 
is caused mainly by the high number of AKs and the 
wider range of costs included in our study. New deve-
lopments, e.g. daylight PDT for individual cases, may 
reduce these costs in the future.
Since all treatments appeared to be effective in the 
different treatment groups, patient characteristics and 
costs could play an important part in treatment choice. 
Since, at present, MAL-PDT is regarded as a costly 
treatment, this therapy is preferred for specific cases, 
e.g. patients with extensive or therapy-resistant field 
cancerization, or who are not compliant or able to 
perform treatment at home. Otherwise, 5-FU appears 
to be the least costly treatment that is effective in cases 
of multiple AK.
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